Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5599 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99SMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1, binding to this target with a dissociation constant (Kd) of 37.4 μM. It demonstrates efficacy in inhibiting the proliferation of cancer cells and tumor progression. Specifically, SMIP34 is effective in breast cancer research, showing activity against wild-type (WT), mutant (MT) estrogen receptor-positive (ER+), and treatment-resistant (TR)-ER+ breast cancers.</p>Fórmula:C25H32ClN5O3Cor e Forma:SolidPeso molecular:486.01Soquelitinib
CAS:<p>Soquelitinib (CPI-818) is a selective ITK inhibitor， inhibits tumor growth,T-cell, up-regulatCXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.</p>Fórmula:C25H30N4O4S2Pureza:99.54%Cor e Forma:SolidPeso molecular:514.66HSP90-IN-10
<p>HSP90-IN-10 is a potent HSP90 inhibitor, targeting HCC1954 cells (IC50: 6 μM) and inducing apoptosis, sparing normal cells.</p>Fórmula:C30H26FN3O6Cor e Forma:SolidPeso molecular:543.54TP-030-1
CAS:<p>TP-030-1, RIPK1 inhibitor: K(i) hRIPK1 at 3.9nM, IC50 mRIPK1 at 4.2μM; targets inflammation, neurodegeneration research.</p>Fórmula:C23H22N4O3Cor e Forma:SolidPeso molecular:402.45XPO1-IN-1
<p>XPO1-IN-1: an oral MM.1S cell inhibitor (IC50: 24 nM), induces apoptosis, stable metabolism, good pharmacokinetics.</p>Fórmula:C20H15F6N5O3SCor e Forma:SolidPeso molecular:519.42Triphen diol
CAS:<p>Triphen diol, a phenol diol, fights pancreatic cancer & cholangiocarcinoma, inducing apoptosis via caspase-dependent & -independent paths.</p>Fórmula:C22H20O4Cor e Forma:SolidPeso molecular:348.39SM-433 hydrochloride
<p>SM-433 hydrochloride, a Smac mimetic & IAP inhibitor, binds XIAP BIR3; potent IC50 <1 μM. (Patent WO2008128171A2)</p>Fórmula:C32H44ClN5O4Cor e Forma:SolidPeso molecular:598.18TP-030-2
CAS:<p>TP-030-2 is a RIPK1 inhibitor (human K i =0.43 nM ; mouse IC 50 =100 nM) .</p>Fórmula:C23H21BrN4O3Cor e Forma:SolidPeso molecular:481.34BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Fórmula:C30H32N6O4Cor e Forma:SolidPeso molecular:540.61PKM2 modulator 2
CAS:<p>PKM2 modulator 2 (compound C599) is a potent inhibitor of PKM2, displaying antiproliferative activity and inducing apoptosis. This compound holds potential for research in glioblastoma.</p>Fórmula:C21H13FN4O3Cor e Forma:SolidPeso molecular:388.351DDO-8958
CAS:<p>DDO-8958 is an orally active and selective BET BD1 inhibitor, exhibiting a KD of 5.6 nM for BRD4 BD1. It shows low nanomolar inhibitory activity across all BET BD1 bromodomains except for BRDT BD1. DDO-8958 inhibits tumor cell proliferation and migration, induces apoptosis and cell cycle arrest, and demonstrates antitumor activity.</p>Fórmula:C22H22FN5O2Cor e Forma:SolidPeso molecular:407.441Caspase-3 activator 4
CAS:<p>Caspase-3 Activator 4 (compound 4o) is an effective caspase-3 activator that can cross the blood-brain barrier. This compound exhibits antiproliferative activity and can induce cell apoptosis (apoptosis). Additionally, Caspase-3 Activator 4 enhances the gene expression of TNF-α and reduces the expression of cleaved caspase-3/caspases 3.</p>Fórmula:C31H27N5O3Cor e Forma:SolidPeso molecular:517.58Apoptosis inducer 36
CAS:<p>Apoptosisinducer 36 (Compound 42) exhibits anti-leukemic activity by reducing leukemia stem cells (LSC) and inducing differentiation. It inhibits proliferation of AML cells by causing cell cycle arrest in the G1 phase, and induces PANoptosis, which includes apoptosis, pyroptosis, and necrosis.</p>Fórmula:C23H40O3SiCor e Forma:SolidPeso molecular:392.647EMT inhibitor-3
CAS:<p>EMT inhibitor-3 (compound 11i) is an epithelial-mesenchymal transition (EMT) inhibitor that effectively suppresses the proliferation, migration, and invasion of SK-N-SH neuroblastoma cells, with an IC50 value of 2.5 μM. It induces mitochondrial-mediated intrinsic apoptosis in tumor cells by enhancing the Bax/Bcl-2 protein expression ratio, promoting the release of cytochrome C from mitochondria, and activating caspase 9 and caspase 3. EMT inhibitor-3 is applicable for cancer research.</p>Fórmula:C29H21F2N3O4SeCor e Forma:SolidPeso molecular:592.45CLM3
CAS:<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Fórmula:C21H21N5Cor e Forma:SolidPeso molecular:343.43Anti-inflammatory agent 16
<p>Compound 14 is a peptidomimetic that significantly lowers TNFα, NO, CD40, and CD86, showcasing strong anti-inflammatory effects.</p>Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.44TLBC
CAS:<p>TLBC, a borane-chalcone derivative, exhibits dose-dependent inhibitory effects across various glioma cell lines with IC50 values ranging from 5.5 to 25.5 μM. TLBC induces apoptosis independently of alterations in the tumor suppressor factor p53.</p>Fórmula:C15H12BIO3Cor e Forma:SolidPeso molecular:377.97LL-Z 1640-4
CAS:A signal-specific JNK/p38 pathway and TAK 1 inhibitorFórmula:C19H24O7Pureza:98%Cor e Forma:SolidPeso molecular:364.39STAT3-IN-9
<p>STAT3-IN-9 hinders STAT3 at Tyr705, doesn't affect STAT1 Tyr701, induces apoptosis, and arrests cells in G2/M phase.</p>Fórmula:C22H21N3O4Cor e Forma:SolidPeso molecular:391.42JH-XVII-10
<p>JH-XVII-10: potent, oral DYRK1A/B inhibitor (IC50: 3/5 nM), shows antitumor activity in HNSCC.</p>Fórmula:C21H16F4N8OCor e Forma:SolidPeso molecular:472.4Etalocib sodium
CAS:Etalocib (LY293111) sodium is an orally active leukotriene B4 (LTB4) receptor antagonist with a Ki value of 25 nM for inhibiting [3H]LTB4 binding. It exhibits an IC50 of 20 nM against LTB4-induced calcium mobilization. Additionally, Etalocib sodium can induce apoptosis.Fórmula:C33H32FNaO6Cor e Forma:SolidPeso molecular:566.59AKN-028 acetate
<p>AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.</p>Fórmula:C19H18N6O2Cor e Forma:SolidPeso molecular:362.39Mcl-1 inhibitor 22
CAS:<p>Mcl-1 inhibitor22 (Example 36) is an MCL-1 inhibitor that suppresses its anti-apoptotic function by blocking the interaction between MCL-1 and pro-apoptotic proteins. It exhibits antiproliferative activity against various cancer cell lines and can be utilized for cancer research.</p>Fórmula:C33H33ClFN3O4Cor e Forma:SolidPeso molecular:590.084Topo I/COX-2-IN-2
<p>Compound W10 is a dual inhibitor of Topo I (IC50: 0.90μM) and COX-2 (IC50: 2.31μM), inducing cancer cell apoptosis via mitochondria.</p>Fórmula:C24H25ClN4OCor e Forma:SolidPeso molecular:420.93MA242
CAS:<p>MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).</p>Fórmula:C26H21ClF3N3O5SPureza:98%Cor e Forma:SolidPeso molecular:579.98ZSH-512
CAS:<p>ZSH-512 is a potent inhibitor of RARγ with antiproliferative properties. It induces apoptosis and reduces the expression of CD133, NANOG, SOX2, and EPCAM proteins. ZSH-512 exhibits anticancer activity and shows potential for colorectal cancer research.</p>Fórmula:C20H21N3O3SCor e Forma:SolidPeso molecular:383.464Topo II/HDAC-IN-1
CAS:Topo II/HDAC-IN-1 (7d) demonstrates potent dual inhibitory effects on Topo II and HDAC, while Topo II/HDAC-IN-1 (8d) effectively induces apoptosis [1].Fórmula:C15H16N4O3SCor e Forma:SolidPeso molecular:332.38Anticancer agent 44
<p>Anticancer agent 44 induces apoptosis, is selective, cytotoxic to cancer cells, and minimally toxic to human lymphocytes.</p>Fórmula:C22H13Cl2N3O5S2Cor e Forma:SolidPeso molecular:534.39Necrosis inhibitor 3
CAS:<p>Necrosis Inhibitor 3 (compound B3) effectively inhibits necrosis, demonstrating an IC50 of 0.29 nM in HT29 cells [1].</p>Fórmula:C25H26N4O4SCor e Forma:SolidPeso molecular:478.56GQN-B37-E
CAS:<p>GQN-B37-E is an effective selective binder and inhibitor of MCL-1. It binds to the BH3-binding domain of MCL-1. GQN-B37-E demonstrates binding affinity for MCL-1 within the sub-micromolar range (Ki= 0.6 μM), yet shows negligible binding to BCL-2 or BCL-XL.</p>Fórmula:C29H23ClN4O4Cor e Forma:SolidPeso molecular:526.97ZIF-8
CAS:<p>ZIF-8 is an anticancer agent that can inherently trigger pyroptosis through a caspase-1/gasdermin D (GSDMD)-dependent pathway.</p>Fórmula:C4H6N2ZnCor e Forma:SolidPeso molecular:147.513VDR agonist 1
CAS:<p>Compound 28 is a nonsteroidal VDR agonist with 690 nM potency, inducing cell cycle arrest and apoptosis in MCF-7 cells.</p>Fórmula:C32H51N3O2Pureza:98%Cor e Forma:SolidPeso molecular:509.77WEHI-9625
CAS:<p>WEHI-9625 is a tricyclic sulfone small molecule apoptosis inhibitor (EC50: 69 nM).</p>Fórmula:C34H27NO5S2Pureza:98%Cor e Forma:SolidPeso molecular:593.71WF-47-JS03
<p>WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.</p>Fórmula:C30H38N6O2Cor e Forma:SolidPeso molecular:514.66Caspase-3-IN-2
CAS:<p>Caspase-3-IN-2 (Compound 4d) acts as an inhibitor of α-Chymotrypsin. It also exhibits inhibitory activity against HIV protease and caspase 3, with inhibition rates of 57% and 51% respectively at a concentration of 100 μM.</p>Fórmula:C10H6ClNO5Cor e Forma:SolidPeso molecular:255.611Sinulatumolin E
CAS:<p>Sinulatumolin E, a terpenoid, inhibits TNF-α (IC 50: 3.6 μM); has anti-inflammatory properties.</p>Fórmula:C15H22O2Cor e Forma:SolidPeso molecular:234.33ASK1-IN-8
CAS:<p>ASK1-IN-8 (Compound 35) is an orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 value of 1.8 nM. In a mouse liver injury model induced by Acetaminophen, ASK1-IN-8 significantly reduces plasma alanine aminotransferase (ALT) levels, offering liver protection. This compound is useful for research in liver disease-related fields.</p>Fórmula:C26H32N8O2Cor e Forma:SolidPeso molecular:488.585PROTAC FKBP Degrader-3
CAS:<p>PROTAC FKBP Degrader-3, with FKBP and VHL binding groups linked, is a potent FKBP degrader.</p>Fórmula:C68H90N6O17SPureza:98%Cor e Forma:SolidPeso molecular:1295.54NDs-IN-1
CAS:NDs-IN-1 (Compound 3g) is a novel non-covalent multi-target inhibitor that inhibits the activities of key enzymes such as hBACE-1, hAChE, and hMAO-B, and is primarily used in the study of neurodegenerative diseases [1].Fórmula:C20H18N2O2Peso molecular:318.37Aeroplysinin 1
CAS:<p>Aeroplysinin I is an antibacterial compound from the sponge. It has cytotoxic activity against colon cancer cells by promoting β-catenin degradation.</p>Fórmula:C9H9Br2NO3Cor e Forma:SolidPeso molecular:338.98PI4KIII β inhibitor 4
CAS:<p>PI4KIII beta inhibitor 4 (Compound 16) is a selective inhibitor of PI4KIIIβ with an IC50 of 0.005 μM. By inhibiting the PI3K/AKT pathway, PI4KIII beta inhibitor 4 induces apoptosis, causes cell cycle arrest, and triggers autophagy in tumor cells. This compound is applicable for tumor research.</p>Fórmula:C24H36N4O6S2Cor e Forma:SolidPeso molecular:540.696PD-1/PD-L1-IN-55
CAS:<p>PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. It enhances IFN-γ secretion and decreases the proportion of late apoptosis due to PD-L1.</p>Fórmula:C25H23ClN2O3Cor e Forma:SolidPeso molecular:434.92L5-DA
<p>L5-DA, a G-quadruplex ligand, stabilizes G4s in HeLa cells, induces apoptosis, and is cytotoxic with an IC50 of 4.3 μM.</p>Fórmula:C32H34N6O2Cor e Forma:SolidPeso molecular:534.65HDAC/PSMD14-IN-1
CAS:<p>HDAC/PSMD14-IN-1 is a derivative of gambogic acid. It serves as an orally active dual inhibitor targeting PSMD14 and HDAC1, with IC50 values of 238.7 nM and 141.2 nM, respectively. The compound exhibits significant cytotoxicity against ESCC cell lines (IC50: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). Additionally, HDAC/PSMD14-IN-1 can induce apoptosis. In KYSE30 cell xenograft models in mice, it displays antitumor activity. HDAC/PSMD14-IN-1 is useful for researching esophageal cancer treatment.</p>Fórmula:C20H24N4O3S2Cor e Forma:SolidPeso molecular:432.56PD-1/PD-L1-IN-15
<p>PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy.</p>Fórmula:C32H30N4O3Cor e Forma:SolidPeso molecular:518.61MY-875
<p>MY-875 inhibits microtubule formation, binds like colchicine (IC50: 0.92 μM), activates Hippo pathway, and induces apoptosis with anticancer properties.</p>Fórmula:C21H25NO6Cor e Forma:SolidPeso molecular:387.43TAS-117 hydrochloride
<p>TAS-117 HCl: potent oral Akt inhibitor (Akt1 IC50: 4.8nM, Akt2: 1.6nM, Akt3: 44nM), boosts anti-myeloma effects, induces cell death.</p>Fórmula:C26H25ClN4O2Cor e Forma:SolidPeso molecular:460.96Tubulin inhibitor 13
CAS:<p>Tubulin inhibitor 13 (E27), IC50 16.1 μM, blocks tubulin polymerization, cancer cell migration, and invasion, induces apoptosis.</p>Fórmula:C25H21N3O4Cor e Forma:SolidPeso molecular:427.45PIM-1/HDAC-IN-1
<p>PIM-1/HDAC-IN-1 (4d): inhibits PIM-1 (IC50: 343.87nM), HDAC1 (63.65nM), HDAC6 (62.39nM); induces apoptosis in MCF-7 cells.</p>Fórmula:C22H19N3O3Cor e Forma:SolidPeso molecular:373.4Topo I-IN-1
<p>Topo I-IN-1 (14d) is a powerful Topo I inhibitor with antitumor effects and DNA intercalation, inducing apoptosis.</p>Fórmula:C20H14BrN3O2Cor e Forma:SolidPeso molecular:408.25Minnelide
CAS:<p>Minnelide is a prodrug of triptolide,and shows potent antitumor activity in a number of tumor types.</p>Fórmula:C21H25Na2O10PPureza:98.49% - 99.59%Cor e Forma:SolidPeso molecular:514.37VEGFR-2-IN-52
CAS:<p>VEGFR-2-IN-52 (compound 14d) serves as a powerful inhibitor of VEGFR-2, exhibiting an IC 50 of 191.1 nM. It effectively reduces the protein expression levels of p-VEGFR-2, MMP9, p-ERK1/2, and p-MEK1. In addition, VEGFR-2-IN-52 demonstrates cytotoxic properties by inducing apoptosis and arresting the cell cycle at the G0/G1 phase, and it enhances the levels of ROS.</p>Fórmula:C20H25ClN4O2SCor e Forma:SolidPeso molecular:420.96XJTU-L453
CAS:<p>XJTU-L453, a PI3Kα inhibitor, exhibits an IC50 of 0.4 nM. It inhibits the proliferation of breast cancer cell lines T47D and MCF7, with IC50 values of 0.2 μM and 0.5 μM respectively. Additionally, XJTU-L453 disrupts the PI3K pathway, leading to cell cycle arrest and cell apoptosis (apoptosis). It also demonstrates antitumor activity in MCF7 xenograft mice.</p>Fórmula:C22H22N4O3Cor e Forma:SolidPeso molecular:390.44Akt/NF-κB/JNK-IN-1
<p>Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signalling pathways.Akt/NF-κB/JNK-IN-1 exhibits an inhibitory effect on nitric oxide</p>Fórmula:C22H22N2O6Cor e Forma:SolidPeso molecular:410.42JND4135
CAS:<p>JND4135, a type II TRK inhibitor, exhibits IC50 values targeting TRKA, TRKB, and TRKC at 2.79, 3.19, and 3.01 nM, respectively. It can overcome resistance due to TRKxDFG and other mutations in the BaF3 stable model, inhibiting the phosphorylation of TRKs WT, xDFG mutations, and their downstream signaling molecules. Additionally, JND4135 induces G0/G1 phase arrest and cell apoptosis (apoptosis) in BaF3–CD74-TRKA-G667C cells. This compound also demonstrates antitumor activity in a BaF3-CD74-TRKA-G667C mouse xenograft model by suppressing tumor growth.</p>Fórmula:C37H39N7OCor e Forma:SolidPeso molecular:597.75Bcl-2-IN-7
<p>Bcl-2-IN-7 inhibits Bcl-2, encourages apoptosis in cancer cells, and has anti-tumor activity with various IC50 values.</p>Fórmula:C24H22N4O5S2Cor e Forma:SolidPeso molecular:510.59ERK-MYD88 interaction inhibitor 1
CAS:<p>ERK-MYD88 Interaction Inhibitor 1, an agent that disrupts the interaction between ERK and MYD88, has demonstrated the ability to trigger an HRI-mediated integrated stress response (ISR) that specifically promotes immunogenic cell apoptosis (apoptosis) in cancer cells. Additionally, in models using Lewis lung cancer mice, this compound has been shown to stimulate anti-tumor T cell responses, thereby exhibiting significant anti-tumor activity.</p>Fórmula:C22H21N5O2Cor e Forma:SolidPeso molecular:387.43Gallium 8-Hydroxyquinolinate
CAS:<p>Gallium 8-Hydroxyquinolinate is an inducer of apoptosis that initiates both p53-dependent and independent cell death in cancer cells through the induction of Ca2+ signaling transduction. In addition to its apoptotic properties, this compound's nanostructures exhibit excellent optical performance, making it suitable for use in tumor research.</p>Fórmula:C27H18GaN3O3Cor e Forma:SolidPeso molecular:502.17Mcl-1 inhibitor 9
CAS:<p>Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM.</p>Fórmula:C32H39ClN2O5SCor e Forma:SolidPeso molecular:599.18CDK2-IN-9
<p>CDK2-IN-9: potent CDK2 inhibitor (IC50: 0.63 μM), anti-proliferative, arrests S/G2M cell cycle, induces apoptosis, promising for melanoma study.</p>Fórmula:C21H16ClN3O4SCor e Forma:SolidPeso molecular:441.89DWP-05195
CAS:<p>DWP-05195 is a TRPV1 antagonist capable of inhibiting pain signal transduction. Additionally, it induces ER stress-dependent apoptosis in human ovarian cancer cells via the ROS-p38-CHOP pathway.</p>Fórmula:C18H10BrF3N4Cor e Forma:SolidPeso molecular:419.2Oxamic acid
CAS:<p>Oxamic acid is an inhibitor of LDH-A and exhibits antitumor activity. It demonstrates antiproliferative effects on cancer cells and can induce apoptosis.</p>Fórmula:C2H3NO3Cor e Forma:SolidPeso molecular:89.05Lepidozin G
<p>Lepidozin G blocks cancer growth (IC50=4.2-5.7μM) and triggers apoptosis in PC-3 cells via mitochondria.</p>Fórmula:C30H48O4Cor e Forma:SolidPeso molecular:472.7DHU-Se1
<p>DHU-Se1: potent anti-inflammatory, releases reactive selenium from macrophages, inhibits iNOS/TNF-α, blocks M0 to M1 polarization.</p>Fórmula:C23H23N3OSSeCor e Forma:SolidPeso molecular:468.47T0080
CAS:<p>T0080 is an FPR-1 antagonist. It reduces apoptosis (Apoptosis) and inhibits the production of reactive oxygen species (ROS) and pro-inflammatory cytokines (TNF-α and IL-1β) in plaque macrophages within ApoE−/− mouse models, thereby slowing the progression of atherosclerosis.</p>Fórmula:C24H22F3N3O3Cor e Forma:SolidPeso molecular:457.45PAK4-IN-5
<p>PAK4-IN-5 (Compound 12i) is a potent inhibitor of PAK4 (IC50: PAK4 at 7.68 nM, PAK1 at 1872.01 nM) that forms stable interactions with the PAK4 enzyme. This compound effectively inhibits the proliferation and migration potential of MDA-MB-231 cells by hindering the phosphorylation of PAK4 and LIMK1. Additionally, PAK4-IN-5 arrests the cell cycle in the G0/G1 phase, induces apoptosis, and prompts the production of reactive oxygen species. The LD50 in mice is greater than 500 mg/kg (oral).</p>Fórmula:C31H28ClN5OCor e Forma:SolidPeso molecular:522.04CB-184
CAS:<p>CB-184 is a selective ligand for sigma-2 (σ2) receptors, with Ki values of 7436 nM for sigma-1 (σ1) and 13.4 nM for sigma-2 (σ2), and it promotes apoptosis with antitumor activity.</p>Fórmula:C22H21Cl2NO2Cor e Forma:SolidPeso molecular:402.31Antitumor agent-72
CAS:<p>Antitumor agent-72 (compound 6w) is a potent anticancer agent that exhibits its anticancer activity by inducing apoptosis via caspase-3 activation and PARP</p>Fórmula:C25H20ClNO6Cor e Forma:SolidPeso molecular:465.88Lysosomal P-gp targeted agent 1
CAS:<p>Lysosomal P-gp targeted agent 1 (Compound 14) is an antitumor drug that targets lysosomal P-glycoprotein (Pgp). It is selectively transported to lysosomes via overexpressed Pgp, releasing nitric oxide that generates reactive oxygen species (ROS), causing lysosomal membrane permeabilization (LMP) and inducing apoptosis. This compound can overcome resistance mediated by P-glycoprotein, leading to cell cycle arrest while maintaining relatively low toxicity to normal cells. It exhibits antitumor activity by significantly inhibiting tumor growth.</p>Fórmula:C39H34N2O9SCor e Forma:SolidPeso molecular:706.76Pan-Trk-IN-3
<p>Pan-Trk-IN-3: potent Trk inhibitor (IC50: 2-26 nM), effective against drug-resistant mutants, induces apoptosis, anti-tumor effects.</p>Fórmula:C29H31ClN8O3Cor e Forma:SolidPeso molecular:575.06VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Fórmula:C24H18N6O2SCor e Forma:SolidPeso molecular:454.5SILA-123
CAS:<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Fórmula:C24H25N5O2Cor e Forma:SolidPeso molecular:415.49Anticancer agent 68
CAS:<p>Compound 12, an anticancer agent, halts G2/M phase, triggers cell death, and activates p53 & PTEN for tumor suppression.</p>Fórmula:C20H18ClNO5Cor e Forma:SolidPeso molecular:387.81RMS5
CAS:<p>RMS5: hambanine analogue, inhibits P-gp, anti-cancer with cytotoxic, anti-proliferative effects, reduces Bcl-2 proteins, cleaves PARP.</p>Fórmula:C35H38N2O5SCor e Forma:SolidPeso molecular:598.75Antitumor agent-78
<p>Antitumor agent-78 blocks GPx-4, raises COX2, triggers apoptosis, halts EMT, and stifles cancer cell growth and migration.</p>Cor e Forma:SoildCasuarinin
CAS:<p>Casuarinin, an ellagitannin found in pomegranates and certain Casuarina/Stachyurus plants, is a carbonic anhydrase inhibitor and astringent.</p>Fórmula:C41H28O26Cor e Forma:SolidPeso molecular:936.65Nenocorilant
CAS:<p>Nenocorilant (Relacorilant) is an orally active glucocorticoid receptor (GR) antagonist (Ki: 0.15 nM). Nenocorilant can be used to study tumours.</p>Fórmula:C26H21F4N7O3SCor e Forma:SolidPeso molecular:587.55FLT3-ITD-IN-3
CAS:<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Fórmula:C27H21ClF2N6O5Cor e Forma:SolidPeso molecular:582.943RET-IN-7
CAS:<p>RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice through</p>Fórmula:C22H24ClFN6O2Cor e Forma:SolidPeso molecular:458.92ADH-6
CAS:<p>ADH-6, a tripyridylamide, disrupts mutant p53 aggregates in cancer cells, reviving its function and inducing apoptosis.</p>Fórmula:C29H36N8O9Cor e Forma:SolidPeso molecular:640.64HP590
CAS:<p>HP590: potent oral STAT3 inhibitor, IC50=27.8 nM, blocks ATP, IC50=24.7 nM, hinders gastric cancer growth, triggers cell death.</p>Fórmula:C29H24F6N4O3Cor e Forma:SolidPeso molecular:590.52TI17
CAS:<p>TI17 is a selective TRIP13 inhibitor with anticancer activity and inhibits proliferation of multiple myeloma (MM) cells</p>Fórmula:C23H22N2O3Pureza:98.00%Cor e Forma:SolidPeso molecular:374.43GP130-IN-1
CAS:<p>GP130-IN-1 (compound 49) is an effective inhibitor of GP130, demonstrating significant in vitro anti-tumor activity and higher selectivity compared to Bazedoxifene. It induces ultrastructural changes in cells, leading to a time-dependent arrest of the cell cycle at the G0/G1 phase, and triggers both apoptosis and autophagy. GP130-IN-1 is useful for research on triple-negative breast cancer.</p>Fórmula:C21H10F5NO3Cor e Forma:SolidPeso molecular:419.30CRT0066101
CAS:<p>CRT0066101 is a potent, orally active PKD inhibitor with IC 50 values of 1 nM, 2.5 nM, and 2 nM for PKD1, PKD2, and PKD3, respectively [1]. Additionally, it inhibits PIM2 with an IC 50 of approximately 135.7 nM and demonstrates anticancer effects [2].</p>Fórmula:C18H22N6OCor e Forma:SolidPeso molecular:338.41ABL-L
CAS:<p>ABL-L is able to induce apoptosis in human laryngeal cancer cells using a p53-dependent pathway.</p>Fórmula:C29H46O6Cor e Forma:SolidPeso molecular:490.67CHI-KAT8i5
CAS:<p>CHI-KAT8i5 is a selective inhibitor of KAT8 with a KD of 19.72 μM. It induces apoptosis (Apoptosis) in a dose-dependent manner. CHI-KAT8i5 can inhibit tumor growth in esophageal squamous cell carcinoma, colon cancer, melanoma, gastric cancer, non-small cell adenocarcinoma, and liver cancer.</p>Fórmula:C23H29N3O5S3Cor e Forma:SolidPeso molecular:523.688KIM-161
CAS:<p>KIM-161 is a PIK3CA inhibitor. It demonstrates significant antiproliferative activity, with IC50 values of 1.428 and 1.562 µM against PI3KCA-mutant breast cancer cell lines MCF7 and T47D, respectively. KIM-161 induces apoptosis and cell cycle arrest by inhibiting the PI3K/AKT/mTOR signaling pathway, leading to ROS production. It is applicable for research on breast cancer and its PI3KCA-mutant subtypes.</p>Fórmula:C27H25N3O3Cor e Forma:SolidPeso molecular:439.51PSP205
CAS:<p>PSP205 is an effective anticancer agent with cytotoxic properties. It induces apoptosis and triggers autophagy mediated by ER stress. Furthermore, PSP205 enhances the expression of LC3BII protein and increases the expression of CHOP and spliced XBP1 at both mRNA and protein levels.</p>Fórmula:C28H32ClN7O5S2Cor e Forma:SolidPeso molecular:646.181PI3K-IN-35
CAS:<p>PI3K-IN-35 (6l) selectively inhibits PI3K-α, β, δ (IC50: 13.98, 7.22, 10.94 μM), blocks G2/M phase, induces apoptosis, and is useful in leukemia research.</p>Fórmula:C25H23N7O2Cor e Forma:SolidPeso molecular:453.5Tubulin inhibitor 17
<p>Compound 3b inhibits tubulin polymerization, IC50 12.38 µM, with anticancer properties and promotes cell apoptosis.</p>Fórmula:C17H16N2OCor e Forma:SolidPeso molecular:264.32Enpp-1-IN-25
CAS:<p>Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.</p>Fórmula:C15H21N5O4SCor e Forma:SolidPeso molecular:367.423eIF4E-IN-4
CAS:<p>eIF4E-IN-4 (Compound 33) is a selective inhibitor of the eukaryotic initiation factor 4E (eIF4E) with a biochemical activity value of 95 nM. It inhibits cap-dependent mRNA translation with an IC50 of 2.5 μM and is applicable in research on breast cancer, colon cancer, and head and neck cancer.</p>Fórmula:C20H19ClN5O5PCor e Forma:SolidPeso molecular:475.822MJC13
CAS:<p>MJC13 is an FKBP52-targeting agent with antitumor activity, suitable for prostate cancer research.</p>Fórmula:C13H15Cl2NOCor e Forma:SolidPeso molecular:272.17HER2-IN-11
<p>HER2-IN-11 is a psoralen derivative that induces apoptosis. HER2-IN-11 shows light-activated cytotoxicity and also exhibits anti-breast cancer activity [1].</p>Fórmula:C17H11NO6Cor e Forma:SolidPeso molecular:325.27EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Fórmula:C18H21N5O3SCor e Forma:SolidPeso molecular:387.46LSD1-IN-21
<p>LSD1-IN-21: potent LSD1 inhibitor, crosses blood-brain barrier, IC50 of 0.956 μM; lowers TNF-α, anti-cancer, anti-inflammatory.</p>Fórmula:C24H25N5O2SCor e Forma:SolidPeso molecular:447.55EGFR-IN-3
<p>EGFR-IN-3 is an EGFR inhibitor with antitumor activity.EGFR-IN-3 inhibits EGFRwt-TK, induces apoptosis (cell death), and can block cells in the G2/M phase.</p>Fórmula:C24H18F4N6O2SPureza:98.1%Cor e Forma:SolidPeso molecular:530.5PD-L1/HDAC6-IN-1
CAS:<p>PD-L1/HDAC6-IN-1 (Compound HP29) is an inhibitor targeting both PD-L1 and HDAC6, effectively disrupting the PD-L1/PD-1 interaction and inhibiting HDAC6 activity, with IC50 values of 26.8 nM and 69 nM, respectively. This compound enhances the cytotoxicity of Jurkat T cells against HepG2 cells, exhibiting an IC50 of 3.4 μM. In rats, PD-L1/HDAC6-IN-1 demonstrates favorable pharmacokinetics, showing a drug exposure level of 871.62 ng·h/mL, and displays antitumor activity in a B16-F10 xenograft mouse model.</p>Fórmula:C27H33N3O3Cor e Forma:SolidPeso molecular:447.569MG28
CAS:<p>MG28 exhibits significant cytotoxic effects, likely stemming from its direct and potent DNA-damaging activity. The compound is utilized in cancer research.</p>Fórmula:C27H25NO3SCor e Forma:SolidPeso molecular:443.56SIRT-IN-7
CAS:<p>SIRT-IN-7 (Compound 7ba) is a SIRT inhibitor. It effectively suppresses the expression of SIRT1, SIRT2, and SIRT3, leading to increased acetylation and activation of p53. Additionally, SIRT-IN-7 inhibits the proliferation of breast cancer cells and induces apoptosis and autophagy, demonstrating antitumor activity.</p>Fórmula:C24H16BrClN2OSCor e Forma:SolidPeso molecular:495.819PD-L1/VISTA-IN-1
CAS:<p>PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.</p>Fórmula:C22H24N4O4Cor e Forma:SolidPeso molecular:408.45PD-1/PD-L1-IN-17
<p>PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 inhibitor (IC50: 26.8 nM).</p>Fórmula:C23H20ClN3O4Cor e Forma:SolidPeso molecular:437.88NSD2-IN-1
CAS:<p>NSD2-IN-1: potent, selective NSD2-PWWP1 inhibitor, IC50 0.11 μM, induces gene expression changes, apoptosis, cell cycle arrest.</p>Fórmula:C29H31N5Cor e Forma:SolidPeso molecular:449.59Mcl-1 inhibitor 21
CAS:<p>Mcl-1 inhibitor21 (Example 1-36) is an Mcl-1 inhibitor with an IC50 of 328 nM. It exhibits pro-apoptotic and anti-proliferative activity against SUDHL5 and SUDHL10 cell lines, making it applicable for cancer research.</p>Fórmula:C32H33N3O4Cor e Forma:SolidPeso molecular:523.622VEGFR-IN-3
CAS:<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Fórmula:C27H28N2O6Cor e Forma:SolidPeso molecular:476.52OICR12694
CAS:<p>OICR12694 (JNJ-65234637) is an orally active inhibitor of B cell lymphoma 6 (BCL6) .</p>Fórmula:C29H28ClF3N8O4Cor e Forma:SolidPeso molecular:645.03SphK1-IN-2
<p>SphK1-IN-2: SphK1 inhibitor, IC50: 19.81 nM; less effective on SphK2. Induces apoptosis, hinders cancer cell growth.</p>Fórmula:C27H30BrNO4SCor e Forma:SolidPeso molecular:544.5Antiproliferative agent-63
CAS:<p>Antiproliferative agent-63 (compound 4d) is a cyclic analog of cannabidiol that acts as an anticancer agent. It demonstrates favorable activity against breast and colorectal cancer. Moreover, this compound can arrest the cell cycle in the G1 phase and induce apoptosis through the mitochondrial pathway in breast cancer cell lines.</p>Fórmula:C27H41NO2Cor e Forma:SolidPeso molecular:411.62NF-κB-IN-4
<p>NF-κB-IN-4 (compound 17) is a potent inhibitor of NF-κB pathway which can cross blood brain barrier (BBB).</p>Fórmula:C18H15FN4OCor e Forma:SolidPeso molecular:322.34EGFR-IN-161
CAS:<p>EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.</p>Fórmula:C33H36Cl2N8O2Cor e Forma:SolidPeso molecular:647.597Antitumor agent-184
CAS:Antitumor Agent-184 (compound 12aa) triggers apoptosis in various cell lines, exhibiting IC50 values of 2.35 μM in B16-F10 cells, 7.32 μM in 4T1 cells, and 10.31 μM in CT26 cells.Fórmula:C22H16N4O2SCor e Forma:SolidPeso molecular:400.45MDK-3345
CAS:<p>MDK-3345 is a reversible covalent inhibitor for Mcl-1.</p>Fórmula:C36H34BN3O7Pureza:98%Cor e Forma:SolidPeso molecular:631.48UCN-01
CAS:<p>inhibitor of Akt, protein kinase C, PDK1 and cyclin-dependent kinases</p>Fórmula:C28H26N4O4Pureza:98%Cor e Forma:SolidPeso molecular:482.53Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride
CAS:<p>Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, comprised of a cereblon ligand based on Thalidomide and a linker, utilized in the synthesis of PROTACs.</p>Fórmula:C21H28ClN5O7Peso molecular:497.93HDAC6/HSP90-IN-2
<p>HDAC6/HSP90-IN-2, a cancer research chemical, inhibits HDAC6 & Hsp90 with IC50s of 105.7 & 61 nM.</p>Fórmula:C19H22N2O5Cor e Forma:SolidPeso molecular:358.39NLRP3-IN-78
CAS:<p>NLRP3-IN-78 (compound 21) is an NLRP3 inhibitor with a 46.72% inhibition rate of GSDMD-induced pyroptosis at 5 μM. It binds to the NLRP3 protein and prevents GSDMD-NT oligomerization. Additionally, NLRP3-IN-78 inhibits GSDMD cleavage and upstream NF-κB signaling, demonstrating anti-inflammatory activity.</p>Fórmula:C12H5Cl2N3O4S2Cor e Forma:SolidPeso molecular:390.222HDAC-IN-9
<p>HDAC-IN-9, a dual tubulin/HDAC inhibitor, impedes A549 cell invasion/migration and shows strong anti-tumor/angiogenic effects.</p>Fórmula:C33H38N2O4Cor e Forma:SolidPeso molecular:526.67HDAC-IN-27 dihydrochloride
CAS:<p>HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active, HDACI class-selective inhibitor, with IC50 values ranging from 0.43 to 3.01 nM for HDAC1-3. This compound exhibits both in vivo and in vitro anticancer activity. HDAC-IN-27 shows significant antiproliferative effects against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). It is useful for research on acute myeloid leukemia (AML).</p>Fórmula:C20H24Cl2N4O2Cor e Forma:SolidPeso molecular:423.336RIPK1-IN-23
CAS:<p>RIPK1-IN-23 (compound 19) is an RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 = 1.7 nM). Additionally, RIPK1-IN-23 exhibits anti-inflammatory properties.</p>Fórmula:C27H22N6O3Peso molecular:478.50tDHU, acid
CAS:<p>tDHU, acid is a dihydropyrimidine cereblon ligand consisting of an E3 ligase ligand and a benzoic acid linker. It serves as an E3 ubiquitin ligase ligand-linker conjugate in the development of PROTACs.</p>Fórmula:C12H12N2O4Peso molecular:248.23hCAIX/XII-IN-5
<p>Coumarin 9a: Selective inhibitor of hCA IX/XII (Ki 93.3/85.7 nM), blocks cancer cell growth, and induces apoptosis.</p>Fórmula:C18H13NO3Cor e Forma:SolidPeso molecular:291.3N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride
CAS:<p>N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride (TLCK hydrochloride) is an irreversible serine protease inhibitor that functions by alkylating the histidine residue at the active site, thus inhibiting trypsin and trypsin-like proteases. It effectively inhibits caspase-3, caspase-6, and caspase-7 with IC50 values of 12.0, 54.5, and 19.3 μM, respectively. Additionally, N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride induces apoptosis in HL-60 cells and prevents the reduction of mitochondrial transmembrane potential during the apoptosis process.</p>Fórmula:C14H22Cl2N2O3SPeso molecular:369.31LA-CB1
CAS:<p>LA-CB1 is a derivative of Abemaciclib that targets CDK4/6 and promotes their degradation via the ubiquitin-proteasome pathway, thereby blocking the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis (Apoptosis). It demonstrates antiproliferative activity against MDA-MB-231 cells with an IC50 of 0.27 µM and effectively inhibits epithelial-mesenchymal transition, cell migration, invasion, and angiogenesis. In highly invasive models like triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth, showing robust dose-dependent antitumor activity. This compound can be utilized in breast cancer research.</p>Fórmula:C28H23ClFN7OCor e Forma:SolidPeso molecular:527.98SLCB050
CAS:<p>SLCB050 is a compound with anticancer activity that inhibits the interaction between DX2 and p14/ARF. It decreases the viability of human lung cancer cells, particularly small cell lung cancer cells, in a p14/ARF-dependent manner, and induces cell apoptosis (apoptosis) and senescence.</p>Fórmula:C21H18O6Cor e Forma:SolidPeso molecular:366.36Sampangine
CAS:<p>Sampangine, an alkaloid, induces apoptosis by causing cell cycle arrest at the G0/G1 phase and inhibits the biosynthesis of heme.</p>Fórmula:C15H8N2OCor e Forma:SolidPeso molecular:232.24Evo312
CAS:<p>Evo312 is an inhibitor of protein kinase C beta I (PKCβI) with an IC50 of 117.34 nM and exhibits dose-dependent characteristics. It acts by inhibiting the expression of the PKCβI protein, which leads to cell cycle arrest and apoptosis in PANC-GR (gemcitabine-resistant pancreatic cancer cells). Evo312 also demonstrates antiproliferative effects in pancreatic cancer cells PANC-1 and PANC-GR, with IC50 values of 0.08 μM and 0.07 μM respectively, while presenting an IC50 of 2.95 μM in normal human pancreatic ductal epithelial cells HPDE6-c7. Additionally, Evo312 has shown antitumor activity in a mouse xenograft model using PANC-GR cells.</p>Fórmula:C21H19N3O3Cor e Forma:SolidPeso molecular:361.39Pim-1 kinase inhibitor 10
CAS:<p>Pim-1 Kinase Inhibitor 10 (compound 13a) acts as both a competitive and non-competitive inhibitor of PIM-1/2 kinase, promoting cell apoptosis and displaying anticancer properties. Additionally, this compound triggers the activation of caspase 3/7 [1].</p>Fórmula:C21H13N3O3Cor e Forma:SolidPeso molecular:355.35Spicamycin
CAS:<p>Spicamycin can be used as a potent inducer of differentiation of human myeloid leukemia cells (HL-60) and murine myeloid leukemia cells (M1).</p>Fórmula:C30H51N7O7Cor e Forma:SolidPeso molecular:621.77TNF-α-IN-14
CAS:<p>TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].</p>Fórmula:C22H26O6Cor e Forma:SolidPeso molecular:386.44WYJ-2
CAS:<p>WYJ-2, a selective agonist for toll-like receptor 2/1 (TLR2/1), demonstrates an EC50 of 18.57 nM in HEK 293T cells transiently co-transfected with human TLR2 and TLR1. It induces pyroptosis and has shown anticancer activity against non-small cell lung cancer (NSCLC) [1].</p>Fórmula:C17H9F2N3O4Cor e Forma:SolidPeso molecular:357.27MTDH-SND1 blocker 2
CAS:<p>MTDH-SND1 blocker 2 (compound C19) is an effective MTDH-SND1 inhibitor with an IC50 value of 487 nM. It binds to the SND1 protein with a Kd of 279 nM and can degrade the SND1 protein. Additionally, MTDH-SND1 blocker 2 exhibits antiproliferative activity and induces apoptosis, showing potential for breast cancer research.</p>Fórmula:C18H12FN3O2SCor e Forma:SolidPeso molecular:353.37GGTI298
CAS:<p>GGTI298 is a potent GGTase I inhibitor; IC50 3μM for Rap1A, >20μM for Ha-Ras.</p>Fórmula:C27H33N3O3SPureza:98%Cor e Forma:SolidPeso molecular:479.63TNF-α-IN-12
CAS:<p>TNF-α-IN-12, a TNF-α inhibitor with an IC50 of 0.1 μM, can reduce TNF-α blood levels [1].</p>Fórmula:C21H22O6Cor e Forma:SolidPeso molecular:370.4Elocalcitol
CAS:<p>Elocalcitol is a calcitriol analog for inhibition of prostate cell growth.</p>Fórmula:C29H43FO2Cor e Forma:SolidPeso molecular:442.65TOPOI/PARP-1-IN-1
CAS:<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>Fórmula:C36H38Br2N4O2Cor e Forma:SolidPeso molecular:718.52Ivaltinostat formic
<p>Ivaltinostat (CG-200745) is an oral panHDAC inhibitor, inducing apoptosis and enhancing cancer drug sensitivity.</p>Fórmula:C25H35N3O6Cor e Forma:SolidPeso molecular:473.56Samuraciclib
CAS:<p>Samuraciclib (CT7001) is an oral CDK7 inhibitor with 41 nM IC50, notable for its high selectivity and potency against breast cancer cells.</p>Fórmula:C22H30N6OCor e Forma:SolidPeso molecular:394.51Ph-Ph+
<p>Ph-Ph+ is a dimerized phenanthroline derivative with antitumor, antibacterial, and antifungal effects.</p>Fórmula:C24H17N4Cor e Forma:SolidPeso molecular:361.42PI3K-IN-58
CAS:<p>PI3K-IN-58 (Compound 17f) is an inhibitor of PI3Kα with an IC50 value of 0.039 μM. It shows significant antiproliferative effects on PC-3, 22RV1, MDA-MB-231, and MDA-MB-453 cell lines with IC50 values of 3.48 μM, 1.06 μM, 2.21 μM, and 0.93 μM, respectively. PI3K-IN-58 induces apoptosis by downregulating the expression of anti-apoptotic proteins Bcl-XL and Bcl-2 while upregulating the expression of the pro-apoptotic protein BAX. This compound is applicable for research in cancer targeting through PI3K pathways.</p>Fórmula:C22H22N6O3SCor e Forma:SolidPeso molecular:450.51GLUT-1-IN-4
CAS:<p>GLUT-1-IN-4 (Compound 13) is an inhibitor of the GLUT-1 glucose transporter that depends on the p53 protein. It suppresses the proliferation of various cancer cells at submicromolar IC50 levels. Additionally, GLUT-1-IN-4 can halt the cell cycle, induce oxidative stress, and promote apoptosis (cell death).</p>Fórmula:C15H10N2O3Cor e Forma:SolidPeso molecular:266.251EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Fórmula:C28H23N7OCor e Forma:SolidPeso molecular:473.53Coprostanone
CAS:<p>Coprostanone (5β-cholestan-3-one) is an active metabolite of hydroxycholesterol and cholesterol. It induces apoptosis in primary gallbladder epithelial cells in dogs. Coprostanone holds potential for research into colon cancer or adenomatous polyps.</p>Fórmula:C27H46OCor e Forma:SolidPeso molecular:386.654BRD1991
CAS:<p>BRD1991 is a chemical compound that specifically disrupts the interaction between Beclin 1 and Bcl-2, thereby inducing autophagy.</p>Fórmula:C33H35Cl2N3O4Cor e Forma:SolidPeso molecular:608.55MA242 free base
CAS:<p>MA242 free base is a dual MDM2/NFAT1 inhibitor that triggers apoptosis in pancreatic cancer cells.</p>Fórmula:C24H20ClN3O3SCor e Forma:SolidPeso molecular:465.95RIPK1-IN-24
CAS:<p>RIPK1-IN-24 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 1.3 μM. It is utilized in research on inflammatory diseases.</p>Fórmula:C26H21FN6O2Cor e Forma:SolidPeso molecular:468.48Lometrexol
CAS:<p>Lometrexol (LY 264618) is an antifolate that inhibits GARFT, blocks purine synthesis, induces apoptosis, and has anticancer properties.</p>Fórmula:C21H25N5O6Pureza:97.76% - 99.56%Cor e Forma:SolidPeso molecular:443.45PF-07328948
CAS:<p>PF-07328948 is a branched-chain keto-acid dehydrogenase kinase (BDK) inhibitor, useful for studying CVD metabolic disorders.</p>Fórmula:C16H8F4O3SPureza:98.42%Cor e Forma:SolidPeso molecular:356.29Milademetan
CAS:<p>Milademetan (DS-3032), an MDM2 inhibitor, exhibits antitumor activity, induces G1 cell cycle arrest and apoptosis, and can be used to study solid tumors.</p>Fórmula:C30H34Cl2FN5O4Pureza:>99.99%Cor e Forma:SolidPeso molecular:618.53Zotatifin
CAS:<p>Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and antitumor properties, inhibiting Sox4 translation and inducing apoptosis.</p>Fórmula:C28H29N3O5Pureza:98.85%Cor e Forma:SolidPeso molecular:487.55Vatalanib hydrochloride
CAS:<p>Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.</p>Fórmula:C20H16Cl2N4Pureza:99.7%Cor e Forma:SolidPeso molecular:383.27HC-5404
CAS:<p>HC-5404 is a potent and selective PERK inhibitor, blocking the activation of the PERK pathway, anti-tumor effects, advanced solid tumors and renal cell Cancer.</p>Fórmula:C24H24F2N4O3Pureza:99.33%Cor e Forma:SolidPeso molecular:454.47SY-5609
CAS:<p>SY-5609 (CDK7-IN-3) is a selective non-covalent CDK7 inhibitor, with weak inhibitory activity against CDK2, CDK9 and CDK12.Cost-effective and quality-assured.</p>Fórmula:C23H26F3N6OPPureza:99.34% - >99.99%Cor e Forma:SolidPeso molecular:490.46UH15-38
CAS:<p>UH15-38 is a potent and selective RIPK3 inhibitor that blocks necroptosis in alveolar epithelial cells triggered by IAV, useful for studying lung inflammation.</p>Fórmula:C26H27N5O2Pureza:99.85%Cor e Forma:SolidPeso molecular:441.53BCL6-IN-3
CAS:<p>BCL6-IN-3: potent BCL6 inhibitor, 70 nM GI50 in SU-DHL4, affects cell functions, antitumor.</p>Fórmula:C24H31ClF2N6O2Pureza:98.17%Cor e Forma:SolidPeso molecular:508.99Tuvusertib
CAS:<p>Tuvusertib (M1774), an oral ATR inhibitor (Ki<1µM), selectively blocks CHK1 phosphorylation, disrupts DNA repair, and induces tumor cell apoptosis.</p>Fórmula:C16H12F2N8OPureza:98.44% - 99.66%Cor e Forma:SolidPeso molecular:370.32JAK2-IN-7
CAS:<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Fórmula:C26H33N7OPureza:99.54%Cor e Forma:SolidPeso molecular:459.59Gemcitabine elaidate hydrochloride
CAS:<p>CP-4126, a lipophilic pro-drug of Gemcitabine, converts to active form by esterases, allowing oral administration with dose-dependent effects.</p>Fórmula:C27H44ClF2N3O5Pureza:98.50% - 99.6%Cor e Forma:SolidPeso molecular:564.11FX-11
CAS:<p>FX-11: potent LDHA inhibitor (Ki 8 μM), activates PKM2, reduces ATP, induces oxidative stress/ROS, cell death, shows antitumor effects.</p>Fórmula:C22H22O4Pureza:98.95%Cor e Forma:SolidPeso molecular:350.41WEHI-539 hydrochloride
CAS:<p>WEHI-539 hydrochloride is a selective Bcl-XL inhibitor with an IC50 of 1.1 nM.</p>Fórmula:C31H30ClN5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:620.18AP1867-3-(aminoethoxy)
CAS:<p>AP1867-3-(aminoethoxy) is a synthetic ligand for FKBP and can be used in the synthesis of PROTAC FKBP12 F36V degrader.</p>Fórmula:C38H50N2O9Cor e Forma:SolidPeso molecular:678.81OBAA
CAS:<p>OBAA is a potent inhibitor of phospholipase A2 (PLA2) with an IC 50 of 70 nM. OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei with an IC 50 of 0.4 μM [1] [2] [3].</p>Fórmula:C28H44O3Pureza:98%Cor e Forma:SolidPeso molecular:428.65(R)-Verapamil hydrochloride
CAS:<p>(R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is an inhibitor of P-Glycoprotein.</p>Fórmula:C27H39ClN2O4Cor e Forma:SolidPeso molecular:491.06Actinonin
CAS:<p>Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces and a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. It also induces apoptosis and inhibits aminopeptidase M, aminopeptidase N, and leucine aminopeptidase, as well as MMP-1, MMP-3, MMP-8, MMP-9, and meprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin exhibits antiproliferative and antitumor activities [1][2][3][4][5].</p>Fórmula:C19H35N3O5Cor e Forma:SolidPeso molecular:385.5PIM-447 dihydrochloride
CAS:<p>PIM-447 dihydrochloride is an orally available and selective inhibitor of pan-PIM kinase(Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38β-Zearalanol
CAS:Beta-Zearalenol, a derivative of zearalenone (ZEA) capable of conjugating with glucuronic acid[2], is a mycotoxin produced by Fusarium spp. It induces apoptosis and oxidative stress in mammalian reproductive cells[1].Fórmula:C18H26O5Cor e Forma:SolidPeso molecular:322.45-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide
CAS:Fórmula:C9H14N4O5Pureza:95%Cor e Forma:SolidPeso molecular:258.2313Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-
CAS:Fórmula:C6H10N2O4PtPureza:98%Cor e Forma:SolidPeso molecular:369.2326Ref: IN-DA00I84B
Produto descontinuadoXMU-MP-3
CAS:<p>XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.</p>Fórmula:C27H27F3N8OCor e Forma:SolidPeso molecular:536.563Carubicin hydrochloride
CAS:<p>Carubicin HCl is an anthracycline antineoplastic antibiotic. Through intercalates into DNA and interacts with topoisomerase II, Carubicin inhibits DNA replication and repair and RNA and protein synthesis.</p>Fórmula:C26H28ClNO10Cor e Forma:SolidPeso molecular:549.95SCH79797
CAS:<p>SCH79797 is a potent and specific protease-activated receptor 1 (PAR1) antagonistwith antimicrobial, anticancer, anti-inflammatory, and neuroprotective effects.</p>Fórmula:C23H25N5Pureza:99.80%Cor e Forma:SolidPeso molecular:371.48Imifoplatin
CAS:<p>Imifoplatin (PT-112) is a platinum compound with antitumor activity and may be used to study prostate cancer and immune system disorders.</p>Fórmula:C6H16N2O7P2PtPureza:≥95.0%Cor e Forma:SolidPeso molecular:485.23A-192621
CAS:<p>A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).</p>Fórmula:C33H38N2O6Pureza:98%Cor e Forma:SolidPeso molecular:558.66Vatiquinone
CAS:<p>Vatiquinone, also known as EPI 743, is an orally bioavailable para-benzoquinone being developed for inherited mitochondrial diseases. The mechanism of action of EPI-743 involves augmenting the synthesis of glutathione, optimizing metabolic control, enhanc</p>Fórmula:C29H44O3Cor e Forma:SolidPeso molecular:440.66Prostaglandin A2
CAS:<p>PGA2 is a naturally occurring prostaglandin in gorgonian corals where it may function in self defense. It is generally not present in mammals. PGA2 has low biological potency in most bioassays, but it does show some antiviral/antitumor activity.[1] At a 25 uM concentration, PGA2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase .[2] It has also been shown to act as a vasodilator with natriuretic properties.[3]</p>Fórmula:C20H30O4Cor e Forma:SolidPeso molecular:334.45Swainsonine
CAS:<p>Swainsonine (Tridolgosir) is an alkaloid isolated from Astragalus membranaceus and is a potent and reversible inhibitor of alpha-mannosidase. swainsonine has antitumour activity and induces apoptosis and cell cycle arrest in the G2/M phase.</p>Fórmula:C8H15NO3Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:173.21RRD-251
CAS:<p>RRD-251 is an Rb-Raf-1 interaction inhibitor that induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine[1].</p>Fórmula:C8H9Cl3N2SCor e Forma:SolidPeso molecular:271.59Thalidomide-5-COOH
CAS:<p>Thalidomide-5-COOH is a useful organic compound for research related to life sciences. The catalog number is T64600 and the CAS number is 1216805-11-6.</p>Fórmula:C14H10N2O6Cor e Forma:SolidPeso molecular:302.242Thalidomide-O-C5-NH2 hydrochloride
CAS:<p>Thalidomide-O-C5-NH2 hydrochloride is a synthetic compound consisting of a ligand-linker conjugate with E3 ligase activity. It combines a cereblon ligand based on Thalidomide and a linker commonly utilized in PROTAC technology.</p>Fórmula:C18H22ClN3O5Cor e Forma:SolidPeso molecular:395.84DB818
CAS:<p>DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.</p>Fórmula:C19H16N6SPureza:98%Cor e Forma:SolidPeso molecular:360.44Ciprofloxacin lactate
CAS:<p>Ciprofloxacin lactate is a useful organic compound for research related to life sciences. The catalog number is T66299 and the CAS number is 97867-33-9.</p>Fórmula:C20H24FN3O6Cor e Forma:SolidPeso molecular:421.43Thalidomide-O-amido-C4-NH2 hydrochloride
CAS:<p>Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].</p>Fórmula:C19H23ClN4O6Pureza:98%Cor e Forma:SolidPeso molecular:438.86MI-773
CAS:<p>MI-773 is a potent inhibitor of the MDM2-p53 protein interaction (PPI) with a high affinity for MDM2 and a Kd value of 8.2 nM. MI-773 exhibits antitumour effects.</p>Fórmula:C29H34Cl2FN3O3Cor e Forma:SolidPeso molecular:562.5Thalidomide-O-C6-COOH
CAS:<p>Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).</p>Fórmula:C20H22N2O7Cor e Forma:SolidPeso molecular:402.403Ac-IETD-CHO TFA
<p>Ac-IETD-CHO TFA is a granzyme B and caspase-8 inhibitor that inhibits caspase8 activity by blocking caspase3 precursor cleavage.Ac-IETD-CHO TFA inhibits Fas-mediated apoptosis.</p>Fórmula:C23H35F3N4O12Cor e Forma:SoildPeso molecular:616.54Yatein
CAS:<p>Yatein inhibits herpes simplex virus type 1 replication by interruption the immediate-early gene expression. Yatein is a lignan isolated from A. chilensis. It also has antiproliferative activity.</p>Fórmula:C22H24O7Pureza:98%Cor e Forma:SolidPeso molecular:400.42Ingenol 3,20-dibenzoate
CAS:<p>Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms that effectively induces the translocation of nPKC-delta, -epsilon, and -theta, as well as PKC-mu, from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2].</p>Fórmula:C34H36O7Cor e Forma:SolidPeso molecular:556.65ENMD-2076 tartrate
CAS:<p>ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.</p>Fórmula:C25H31N7O6Cor e Forma:SolidPeso molecular:525.56Mcl-1 inhibitor 6
CAS:<p>Mcl-1 inhibitor 6 binds Mcl-1 with KD 0.23 nM and Ki 0.02 μM, shows strong selectivity over Bcl-2 family, and demonstrates antitumor efficacy.</p>Fórmula:C26H28ClNO6SCor e Forma:SolidPeso molecular:518.02CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73anti-TNBC agent-2
CAS:<p>Anti-TNBC agent-2 (3j), a purine derivative, acts as an anti-triple negative breast cancer (TNBC) therapeutic.</p>Fórmula:C28H37ClFN7OPureza:98%Cor e Forma:SolidPeso molecular:542.09Ref: TM-T79699
Produto descontinuadoIHMT-MST1-39
CAS:<p>IHMT-MST1-39 is an orally effective MST kinase inhibitor with IC50 values of 42 nM for MST1 and 109 nM for MST2. It activates the AMPK signaling pathway in hepatocytes and inhibits apoptosis in pancreatic β cells. Additionally, IHMT-MST1-39 improves type 1 diabetes in mice induced by Streptozotocin.</p>Fórmula:C20H18F2N6O3SCor e Forma:SolidPeso molecular:460.46Ref: TM-T200512
Produto descontinuadoSMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1 that demonstrates the capability to reduce cell viability and colony formation. Additionally, SMIP34 induces cell apoptosis (apoptosis) and causes cell cycle arrest in the S phase. It reduces the expression of PELP1 and exhibits anti-tumor activity. SMIP34 also has potential for research in triple-negative breast cancer (TNBC).</p>Fórmula:C20H15ClFN5O2SCor e Forma:LiquidPeso molecular:443.88Cyy-272
CAS:<p>Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25, 1.07, and 1.24 μM against JNK1, JNK2, and JNK3, respectively. It exerts anti-inflammatory effects by inhibiting the phosphorylation of JNK, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS). Moreover, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissues caused by high lipid concentrations, further mitigating resultant cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 is utilized in the study of obesity-related myocarditis.</p>Fórmula:C23H23F2N7Cor e Forma:SolidPeso molecular:435.47Ref: TM-T200453
Produto descontinuadoCHMFL-48
CAS:<p>CHMFL-48, an orally active inhibitor of BCR-ABL kinase, demonstrates efficacy against both the wild-type (wt) and various imatinib-resistant mutants. It exhibits potent inhibitory activity, with IC 50 values of 1 nM for the ABL wild-type and 0.8 nM for the ABL T315I mutant. CHMFL-48 operates by inhibiting the autophosphorylation of both wild-type and mutant BCR-ABL, affecting downstream signaling mediators including STAT5 and CRKL. This disruption leads to cell cycle arrest and triggers apoptosis. Given its properties, CHMFL-48 is a promising candidate for research on chronic myeloid leukemia (CML).</p>Fórmula:C31H30F3N7OCor e Forma:SolidPeso molecular:573.61DETD-35
CAS:<p>DETD-35 is a promising chemical compound in anti-melanoma therapy, functioning as an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways. It enhances cancer cell apoptosis (Apoptosis) and diminishes resistance to Vemurafenib in cancer cells. The compound exhibits IC 50 values of 2.7, 6.0, 3.9, 3.1, and 2.5 μM against melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c, respectively. DETD-35 offers significant potential for advancing research in melanoma treatment strategies.</p>Fórmula:C27H24O6Cor e Forma:SolidPeso molecular:444.48Taltobulin
CAS:<p>Taltobulin (HTI-286) is a synthetic analog of the tripeptide cysteine, a microtubule protein inhibitor that inhibits liver tumor cell proliferation in vitro and tumor growth in vivo.Taltobulin is cytotoxic, induces mitotic arrest and apoptosis, and may be used in the study of breast cancer and microtubule tissue-related diseases.</p>Fórmula:C27H43N3O4Pureza:99.86%Cor e Forma:SolidPeso molecular:473.65ZSQ836
CAS:<p>ZSQ836 is a dual covalent inhibitor of CDK12/CDK13 with oral bioactivity, displaying an EC50 value of 32 nM against CDK12. This compound can induce cell apoptosis (apoptosis) and demonstrates in vivo anticancer properties. ZSQ836 is applicable for research in ovarian cancer.</p>Fórmula:C27H28AsClN6OS2Cor e Forma:SolidPeso molecular:627.05Ref: TM-T200333
Produto descontinuado
![Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA00I84B.webp&w=3840&q=75)
